Cook Spectrum v. Arrow Arrowguard Blue
This article was originally published in The Gray Sheet
Cook's central venous catheter impregnated with minocycline and rifampin had one-third the infection rate of Arrow International's catheter impregnated with chlorhexidine and silver sulfadiazine, according to an 817-patient, 12-site study published in the Jan. 7 New England Journal of Medicine. Of the 865 catheters placed into 817 patients, 85% (738) produced culture results that could be evaluated, of which 356 were Cook's and 382 were Arrow's. Twenty-eight of 356 (7.9%) of Spectrum catheters were colonized, versus colonization in 87 of 382 (22.8%) Arrowguard Blue catheters. Fourteen patients also had catheter-related bloodstream infections, of which 3.4% (13) had Arrow devices and 0.3% (1) had a Cook device
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.